AstraZeneca PLC has launched its global Phase III trial of its COVID-19 vaccine candidate, and has addressed rumors that the US Food and Drug Administration could grant it an emergency use authorization (EUA) before this trial is complete.
Announcing the start of the trials recruiting up to 30,000 people in the US, the company pledged on 31 August...







